

# ASCL1 Reorganizes Chromatin to Direct Neuronal Fate and Suppress Tumorigenicity of Glioblastoma Stem Cells

Nicole I. Park, Paul Guilhamon, Kinjal Desai, Rochelle F. McAdam, Ellen Langille, Madlen O'Connor, Xiaoyang Lan, Heather Whetstone, Fiona J. Coutinho, Robert J. Vanner, Erick Ling, Panagiotis Prinos, Lilian Lee, Hayden Selvadurai, Gurnit Atwal, Michelle Kushida, Ian D. Clarke, Veronique Voisin, Michael D. Cusimano, Mark Bernstein, Sunit Das, Gary Bader, Cheryl H. Arrowsmith, Stephane Angers, Xi Huang, Mathieu Lupien, and Peter B. Dirks\*

\*Correspondence: [peter.dirks@sickkids.ca](mailto:peter.dirks@sickkids.ca)  
<http://dx.doi.org/10.1016/j.stem.2017.08.008>

(Cell Stem Cell 21, 209–224; August 3, 2017)

In our original paper, we mistakenly incorporated incorrect catalog information for the TUBB3 antibody into the Key Resources Table. The correct information is as follows: Resource, Anti-TUBB3 antibody (clone TU-20); Source, Millipore; Identifier, Cat#MAB1637; RRID: AB\_2210524. We also mistakenly listed incorrect gRNA targeting sequences for ASCL1 in Table S7. The correct information is as follows: gRNA targeting sequence ASCL1 #1, GGAGCACGTCCCCAACGGCGCGG and gRNA targeting sequence ASCL1 #2, GCAAAGAAACAGGCTGCGGGCGG. This information has now been corrected in our article's Key Resources Table and Table S7 online. We apologize for the oversight.